ArticleFrontiers in immunology2026
IL-34-mediated fibroblast-like synoviocyte-macrophage crosstalk drives bone erosion in rheumatoid arthritis through RANKL-dependent osteoclastogenesis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The crosstalk between fibroblast-like synoviocytes (FLS) and macrophages forms a self-reinforcing vicious feedback loop in the rheumatoid arthritis (RA) immune microenvironment. Upregulated interleukin-34 (IL-34) levels in RA patients correlate with RA severity. This study investigated the roles and mechanisms of IL-34-mediated FLS-macrophage crosstalk in osteoclastogenesis-associated bone erosion in RA. Methods: IL-34 expression in the RA serum and synovial samples and its correlation with disease severity and bone erosion were assessed. Primary FLS were transfected with IL-34 overexpression plasmids or short hairpin RNA (shRNA) targeting IL-34, and cell proliferation, migration, invasion and apoptosis were examined. Then, conditioned medium (CM) from these FLS were incubated with THP-1-differeniated macrophages to evaluate macrophage migration and polarization. FLS, M1 macrophages, and their cocultures were respectively treated with recombinant human IL-34 (rhIL-34), and these CM were incubated with peripheral blood mononuclear cells (PBMCs). Receptor activator of NF-κB ligand (RANKL) concentration and osteoclast differentiation were determined. Additionally, a collagen-induced arthritis mouse model was established and treated with IL-34 neutralizing antibody. The arthritis score, paw swelling, histopathological analysis micro-CT analysis were conducted. Results: Upregulated serum IL-34 level in RA patients was correlated with disease severity and bone erosion. IL-34 overexpression facilitated proliferation, migration and invasion and inhibited apoptosis in FLS. Moreover, CM from IL-34-overexpressing FLS promoted macrophage recruitment and M1 polarization. In contrast, IL-34 silencing showed the opposite results. rhIL-34-stimulated FLS-macrophage coculture exhibited higher RANKL production and enhanced osteoclast differentiation. However, RANKL inhibitor denosumab abolished these effects. IL-34 blockade attenuated RA severity, synovial hyperplasia, macrophage M1 polarization, inflammatory infiltration, and bone erosion in CIA mice. Conclusion: IL-34 accelerates RA progression by regulating FLS-macrophage crosstalk to amplify bone erosion through RANKL-dependent osteoclastogenesis. We suggest that IL-34 blockade as a promising therapeutic strategy for concurrently alleviating synovial hyperplasia, inflammation, and bone erosion in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.